HTB homepage • Conference reports • Articles by subject • Subscribe November 2002 Contents Treatment alerts New safety information for ddI used with ribavirin US FDA issues new safety information for tenofovir co-administration with ddI Conference reports 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, 27-30 September 2002 Immunology and treatment interruption data presented at the 42nd ICAAC Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3 Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL Topical transdermal testosterone gel offers significant clinical benefits in hypogonadal HIV-positive patients BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients Adverse drug reactions and lipodystrophy in children Study suggests Kaletra/Combivir is better tolerated PEP than Combivir/nelfinavir Novel approaches to the inhibition of HIV Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC 4th International Workshop on Drug Reactions and Lipodystrophy in HIV Infection, San Diego, 22-25 September 2002 Leptin, lipodystrophy and insulin resistance A range of treatments for facial lipoatrophy Autopsy evidence confirms that ARVs tackle CNS lesions Antiretrovirals New evidence favours routine measurement of plasma concentrations in salvage therapy to maintain sustained drug levels European Commission approves new boosted saquinavir regimen (1000 mg saquinavir/100 mg ritonavir twice daily) for the treatment of HIV-1 Treatment access Profiteers undermine preferential pricing and make millions diverting cheap drugs sent to Africa Activists win court battle in campaign for generic production of ddI Global AIDS fund facing bankruptcy Women's health HAART enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women PK and drug interactions Milk thistle can reduce levels of indinavir in the blood Side effects Tamoxifen for male breast enlargement? Diet can help reduce lipid levels in people with HAART-related dyslipemia Lipodystrophy syndrome and self-assessment of wellbeing and physical appearance in HIV-positive patients Coinfections and complications Intestinal worm eradication lowers viral load in HIV-positive patients Basic science and immunology Study shows why some immune systems can control HIV through CD8 cells PPAR agonists inhibit HIV replication and TNF-alpha production Many HIV-infected CD4 cells are HIV-specific in patients on HAART Other news The Children’s HIV Association of the UK and Ireland – CHIVA Highlights of the autumn CHIVA meeting Multivitamins limit HIV transmission through breastfeeding for some women Prison health services will be taken over by the NHS from next year Multivitamins limit HIV transmission through breastfeeding for some women On the web Diagnosis and management of hepatitis C HIV-1-associated dementia: a basic science and clinical perspective Clinicians debate antiretroviral tactics and toxicities, resistance testing, and hepatitis virus coinfection Lymphoma in the setting of HIV disease Mitochondrial toxicity in HAART Mechanisms of T-cell depletion and repletion in HIV disease HAART interruption strategies: how, when & why? HIV/AIDS related Spanish language sites, from thirteen different countries. New treatment information from Visionary Health Concepts The Guide to Lipodystrophy in HIV LIPOWatch Fat in the blood Current status of ARV treatment interruption and intermittent therapy strategies Pathogenesis and epidemiology of metabolic abnormalities Management of morphologic changes during antiretroviral therapy: insights from etiology Entry inhibitors Mitochondrial toxicity HIV medicine after the Barcelona conference: interview with Howard Grossman MD Once-daily antiretroviral options PDFs Volume 3 Number 9 November 2002 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
